{
  "drug_name": "Dalbavancin",
  "tradename": "Dalvance, Xydalba",
  "usage_and_dosing": {
    "general": [
      "Dalbavancin is a long-acting parenteral lipoglycopeptide antibiotic.",
      "Approved for acute skin and skin structure infections.",
      "An alternative antibiotic for drug resistant genotypes.",
      "If unable to directly test susceptibility, in vitro susceptibility to vancomycin is acceptable as a surrogate (Diagnostic Microbiol Infect Dis 2015;82:73).",
      "Dalbavancin shown active in vitro and in clinical infections due to:",
      "Staphylococcus aureus: MSSA and MRSA",
      "Streptococcus pyogenes",
      "Streptococcus agalactiae (Group B Strep.)",
      "Streptococcus dysgalactiae",
      "Streptococcus anginosus group",
      "Vancomycin-susceptible Enterococcus faecalis",
      "Also active in vitro against:",
      "Enterococcus faecium (Vancomycin-susceptible strains only)",
      "Vancomycin-intermediate Staph. aureus (not active vs. Vancomycin-resistant strains)",
      "Once weekly dosing regimen may be a useful alternative for outpatient parenteral therapy (see Comments).",
      "Prepare infusions in D5W only. Do not add to normal saline (drug may precipitate out of solution)."
    ],
    "adult_dose": {
        "skin_and_skin_structure": {
            "two_dose_regimen": "Originally approved as a two-dose regimen: 1000 mg IV once, followed in one week by a dose of 500 mg IV.",
            "single_dose_regimen": "Later approved as a single dose of 1500 mg IV; shown non-inferior to the 2-dose regimen (Clin Infect Dis 62:545, 2016).",
            "infusion": "Infuse doses over 30 minutes."
        },
        "infective_endocarditis": {
            "sequential_therapy": "If used as sequential therapy for infective endocarditis:",
            "options": [
                "Loading dose of 1000 mg IV on day 1, then 500 mg IV once weekly, OR",
                "Loading dose of 1500 mg IV on day 1, then 1000 mg IV every 2 weeks."
            ],
            "infusion": "Infuse doses over 30 minutes."
        }
    },
    "pediatric_dose": {
      "crcl_ge_30": {
        "age_0_to_lt_6_yrs": "22.5 mg/kg x1 dose",
        "age_6_to_lt_18_yrs": "18 mg/kg x1 dose"
      },
      "crcl_lt_30": "Not recommended",
      "max_day": "1500 mg"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "147-258 (terminal)",
    "half_life_esrd": "No data",
    "dose_renal_function_normal": "1 gm IV x1 then 500 mg IV in 7 days, OR 1.5 gm IV x1",
    "crcl_or_egfr": {
        "ge_30": "No dosage adjustment",
        "lt_30_no_hd": "750 mg x1 then 375 mg in 7 days, OR 1125 mg x1"
    },
    "hemodialysis": "No dosage adjustment",
    "capd": "No data",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No data, use caution",
    "severe_impairment_child_pugh_c": "No data, use caution"
  },
  "other_adjustment": [
    "Obesity: See Obesity Dosing Adjustments table."
  ],
  "adverse_effects": [
    "Common (>2%): nausea (5.5%), headache (4.7%), diarrhea (4.4%), rash (2.7%), pruritus (2.1%).",
    "Uncommon (<2%): C. difficile, candidiasis, cytopenias, anaphylactoid reaction, dizziness, bronchospasm, urticaria, eosinophilia, elevated INR, hepatic enzymes; hypoglycemia.",
    "Flushing, urticaria, and pruritus (similar to vancomycin histamine release syndrome) can occur with rapid infusion. Stopping or slowing the infusion may result in cessation of the reaction.",
    "ALT elevations > 3x upper limit of normal (0.8%).",
    "Does not prolong QT interval."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No human data. Toxic in rats at 3.5x human exposure.",
    "lactation": "Probably safe with monitoring, but no data available",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "24-hr AUC/MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "280-300 (1 gm IV, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "93-98",
    "volume_of_distribution_vd_l_kg": "0.11 L/kg (Drugs 2010;70:859)",
    "avg_serum_half_life_hr": "147-258 (terminal)",
    "elimination": "Renal, fecal",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "23443 (1 gm IV, 0-inf)"
  },
  "major_drug_interactions": [
    "None known"
  ],
  "comments": [
      "Extended terminal half-life of this agent allows treatment with two intravenous doses, spaced one week apart, or a single intravenous dose, for treatment of acute bacterial skin and skin structure infections (FDA approved indication).",
      "Emerging interest in use, instead of vancomycin, for outpatient parenteral antimicrobial therapy (OPAT) of susceptible organisms causing SSSIs or infective endocarditis due to susceptible organisms.",
      "No controlled clinical trials",
      "Ref.: Infect Dis Ther 2019;8:171",
      "Dalbavancin is active in vitro vs. Vancomycin-susceptible E. faecium and E. faecalis and is approved for skin and skin structure infections due to the latter.",
      "Caution is advised in patients with history of allergy to other glycopeptide antibiotics because likelihood of cross-sensitivity is unknown."
  ]
}
